早期识别侵袭性垂体腺瘤:单中心经验
该单中心研究纳入582例垂体腺瘤患者,其中102例(18%)被认定为侵袭性垂体腺瘤,中位随访5年。研究发现影像学侵袭是最常见的侵袭行为标志,手术、放疗和药物治疗可使半数患者达到疾病控制,但影像学、临床或非典型特征并未影响结局。
要点
- 侵袭性垂体腺瘤占本中心582例垂体腺瘤患者的18%(102例)。
- 75%的侵袭性垂体腺瘤患者存在周围结构侵犯,以GH分泌型、PRL分泌型和无分泌型为主。
- 手术是最常采用的治疗(总体缓解率24%),放疗后中位3年缓解率45%,药物治疗2年疾病控制率41%。
核心结论
- 作者提出基于影像学、临床和病理特征的综合侵袭性垂体腺瘤定义;影像学侵犯是描述侵袭行为最常见的标志。
- 手术、放疗和药物治疗(后者仅用于分泌型腺瘤)使半数侵袭性腺瘤患者达到疾病控制,尤其是ACTH瘤的手术和GH、PRL分泌型腺瘤的药物治疗。
- 影像学、临床或非典型特征并未影响结局。
研究设计与样本
- 单中心研究,纳入582例垂体腺瘤患者,其中102例(18%)被认定为侵袭性垂体腺瘤(56例男性,46例女性),中位随访5年。
主要发现
- 102例侵袭性垂体腺瘤中,ACTH分泌型14例、GH分泌型18例、PRL分泌型23例、无分泌型47例。
- 全队列中75%的侵袭性垂体腺瘤患者存在周围结构侵犯,尤其是GH分泌型、PRL分泌型和 无分泌型。
- 手术总体缓解率24%,放疗占22%的患者,中位3年缓解率45%;分泌型腺瘤连续2年药物治疗的疾病控制率为41%。
- 24%的病例被定义为非典型腺瘤;典型与非典型腺瘤患者在影像学特征、药物治疗反应和缓解率方面相似。
关键数值与推荐
- 侵袭性垂体腺瘤的判定基于影像学特征(大小、局部侵犯)、病理报告(非典型腺瘤:MIB-1 >3%、p53免疫反应性、核分裂活性增加)和临床方面(对手术、放疗和药物治疗的反应)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pituitary adenomas are usually considered benign tumours, although some of them can exhibit an aggressive behaviour. Patients with clinically aggressive pituitary adenomas are frequently diagnosed with larger masses, and may present an earlier recurrence (or persistence) after surgery. Our aim was to characterise the clinical, histopathological and radiological features of patients with aggressive pituitary adenoma, in order to correlate their clinical behaviour with the response to treatment plan. METHOD: We considered an aggressive pituitary adenoma on the basis of radiological features (size, local invasion), pathological reports (atypical adenoma: MIB-1 >3%, p53 immunoreactivity, increased mitotic activity) and clinical aspects (response to surgery, radiotherapy and medical treatment). RESULTS: Among our cohort of 582 patients, we considered 102 subjects with aggressive pituitary adenomas (18%, 56 male and 46 female): 14 adrenocorticotrophic hormone (ACTH)-secreting, 18 growth hormone (GH)-secreting, 23 prolactin (PRL)-secreting and 47 non-secreting, with a median follow-up of 5 years. In the whole cohort, 75% of patients with aggressive pituitary adenomas presented invasion of surrounding structure, especially GH-secreting, PRL-secreting and non-secreting. Besides invasion, their remission rate after surgery, radiotherapy or medical treatment was similar, irrespective of hormonal secretion. Surgery was the most performed treatment (overall remission rate of 24%), especially in those patients with ACTH- or GH-secreting adenoma, and 22% of patients were submitted to radiotherapy, with a remission rate of 45% after a median of 3 years. Two consecutive years of medical treatment, in patients with secreting pituitary adenoma, achieved disease control in 41% of them. Considering pathological reports, 24% of cases were defined as atypical adenomas; radiological characteristics, responses to medical treatment and remission rates were similar among patients with typical and atypical adenoma. CONCLUSIONS: We proposed a new and comprehensive definition of aggressive pituitary adenoma, based upon radiological, clinical and pathological features. In a selected cohort of patients, radiological invasion resulted in the most common marker to describe the aggressive behaviour of pituitary adenoma. Surgery, radiotherapy and medical treatment (the latter only in secreting adenoma) achieved disease control in half of the patients with aggressive adenoma, especially surgery in those with ACTH-oma and medical treatment in those with GH- and PRL-secreting adenoma. Nevertheless, radiological, clinical or atypical features did not affect the outcome.
引用
- Ceccato F, Regazzo D, Barbot M, et al. Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir (Wien). 2017. PMID: 29170844. doi:10.1007/s00701-017-3396-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。